Old Web
English
Sign In
Acemap
>
authorDetail
>
S Krebs
S Krebs
University of Erlangen-Nuremberg
Biosimilar
Infliximab
Medicine
Immunology
Intensive care medicine
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
P548 Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study
2020
Journal of Crohns & Colitis
Sarah Fischer
S Mesfin
E Klenske
Heike Schmitt
F Vitali
Simon Hirschmann
Andreas Ramming
Sebastian Zundler
Timo Rath
S Krebs
Frank Dörje
Wolfgang Uter
D Nagore
Sebastian Meyer
Markus F. Neurath
Raja Atreya
Show All
Source
Cite
Save
Citations (0)
Effektivität, Immunogenität, Sicherheit und pharmakoökonomische Aspekte beim Switch vom Originalprodukt Infliximab auf das Biosimilar SB2 bei CED-Patienten: 6-Monatsdaten einer prospektiven Kohortenstudie
2018
Zeitschrift Fur Gastroenterologie
Sarah Fischer
E Klenske
Heike Schmitt
F Vitali
Simon Hirschmann
F Koch
A Ramming
Sebastian Zundler
S Krebs
Frank Dörje
D Nagore
Sebastian Meyer
Wolfgang Uter
Markus F. Neurath
Raja Atreya
Show All
Source
Cite
Save
Citations (0)
1